Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) Shares Outstanding (Weighted Average) (2020 - 2025)

Journey Medical's Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $24.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 19.9% year-over-year to $24.5 million, compared with a TTM value of $24.5 million through Dec 2025, up 19.9%, and an annual FY2025 reading of $24.5 million, up 19.9% over the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $24.5 million at Journey Medical, down from $25.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $25.0 million in Q3 2025, with the low at $9.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $17.8 million, with a median of $18.1 million recorded in 2023.
  • Year-over-year, Shares Outstanding (Weighted Average) increased 0.3% in 2021 and then surged 90.65% in 2022.
  • Tracing DERM's Shares Outstanding (Weighted Average) over 5 years: stood at $10.2 million in 2021, then surged by 72.05% to $17.5 million in 2022, then grew by 4.0% to $18.2 million in 2023, then rose by 12.06% to $20.4 million in 2024, then rose by 19.9% to $24.5 million in 2025.
  • Per Business Quant, the three most recent readings for DERM's Shares Outstanding (Weighted Average) are $24.5 million (Q4 2025), $25.0 million (Q3 2025), and $23.3 million (Q2 2025).